SCHEMBL2254967

SCHEMBL2254967

O=C(O)c1ccc(-c2ccc(F)cc2)cc1C(=O)Nc1ccc2c(O)cccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B1 P14061 4/20 0.48
▸ HSD17B2 P37059 4/20 0.48
▸ AKR1C3 P42330 3/20 0.47
▸ AR P10275 2/20 0.47
▸ CBR1 P16152 2/20 0.47
▸ AKR1C1 Q04828 1/20 0.47
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ PYGL P06737 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ESR1 P03372 1/20 0.43
▸ ESR2 Q92731 1/20 0.43
▸ KDR P35968 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ GRIN2D O15399 1/20 0.42
▸ GRIN2A Q12879 1/20 0.42
▸ GRIN2B Q13224 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2255199 0.91 AKR1C3 (0.47) AKR1C3ARCBR1AKR1C1KMT2A
SCHEMBL2253060 0.76 TRPV1 (0.51) KMT2AMEN1RAB9AKDM4EMAPT
SCHEMBL2255733 0.74 PPARA (0.43) KMT2AMEN1KDM4EMAPTGRIN2D
SCHEMBL2251560 0.73 BCL2L1 (0.67) HSD17B1HSD17B2ESR1ESR2LCK
SCHEMBL2251565 0.73 BCL2L1 (0.67) HSD17B1HSD17B2ESR1ESR2LCK
SCHEMBL30726817 0.73 KCNK3 (0.60) KMT2AMEN1NPC1RAB9APYGL
SCHEMBL29674908 0.73 KCNK3 (0.60) KMT2AMEN1NPC1RAB9APYGL
SCHEMBL2257660 0.72 ACLY (0.49) KMT2AMEN1GRIN2DGRIN2AGRIN2B
SCHEMBL12046468 0.71 ALDH1A1 (0.66) KMT2AMEN1KDM4E
SCHEMBL6852586 0.71 LMNA (0.62) KMT2AMEN1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 — — US claimed
EP-1904047-B1 APOPTOSIS PROMOTERS ABBOTT LAB (US) 2013-01-02 — — EP disclosed
US-7989656-B2 Biaryl carboxylic acid apoptosis promoters ABBOTT LABORATORIES (US) 2011-08-02 — — US disclosed
US-20100234456-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2010-09-16 — — US disclosed
US-7750004-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-06 — — US disclosed
US-20070135392-A1 Apoptosis promoters ABBVIE INC. 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234456-A1 APOPTOSIS PROMOTERS MCL1, BAX, BCL2 HSD17B1 2480/4885HSD17B2 3114/4885AKR1C3 3466/4885
US-20070135392-A1 Apoptosis promoters MCL1, BAX, BCL2 HSD17B1 2480/4885HSD17B2 3114/4885AKR1C3 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback